Cue Biopharma is trading 10.31% lower at $24.62, with no clear company-specific catalyst identified for the September 29 decline. - Positive CUE-221 Phase 2 results were announced September 20 and do not establish a cause for the move. - Major indices are down modestly, but none has fallen more than 0.5%, so broad-market pressure alone is not a clear explanation. - Shares closed down 12.61% on September 28, indicating continued weakness.